Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

NPNovaBay Pharmaceuticals, Inc.

$1.95

+0.37 (+23.42%)

D 20Pipeline Score Richly Valued Pharma · Clinical
Market Cap
51.92 M
EPS
-7.43
P/E Ratio
-
Value Trade
1.18 M
SEC Financials
Q3 2025

  • Dilution Risk

    95%

  • Revenue

    521.00 K

  • Total Assets

    3.49 M

  • Total Liabilities

    1.85 M

  • Equity

    1.11 M

  • D/E Ratio

    12,345

36.36 %
Week
36.36 %
1 Month
-92.97 %
3 Month
-74.84 %
6 Month
-99.96 %
5 Year
-100 %
All Time
Cash Data
Critical

  • Cash Position

    2.31 M

  • Monthly Burn

    419.00 K

  • Runway

    1.2 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    Nov 7, 2025
Overview
Volume
637.60 K
52 Week Range
1.11 - 99.75
% held by Insiders
95.11 %
% held by Institutions
5.45 %
Enterprise Value
45.09 M
Total Shares
26.64 M
Short %
4.24 %
Float Shares
15.26 M
Company Description
HQ: 2000 POWELL STREET, SUITE 1150...
Founded:26-10-2007
Employees:14
https://www.novabay.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D20
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
3
Drugs Scored
0.0x
rNPV / MCap
Top 19%
Micro Cap
(rank 734 of 905)
Percentile Rank
NovaBay Pharmaceuticals, Inc. faces pipeline headwinds (20/100), with $500M risk-adjusted pipeline value, led by Auriclosene 0.3% in Bacterial Conjunctivitis (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Auriclosene 0.3%
Small molecule		Bacterial ConjunctivitisPhase 2NCT0187769421% $226M COMPLETED 217 - -Jan 1, 2015 -May 28, 2015
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Example Drug
Example indication for clinical evaluation
Phase 3
2025-12-01
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in NBY
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
NovaBay Pharmaceuticals, Inc. (NBY) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
NBY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NBY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
NBY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
NBY Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
NBY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How NBY ranks across every disease it competes in
Competitive Position is a premium feature
See how NBY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial